FARSLA inhibitors are a diverse group of compounds that interfere with various biological processes, ultimately leading to the inhibition of FARSLA function. These inhibitors affect pathways that are upstream or directly related to FARSLA's role in protein synthesis. For example, rapamycin and compounds such as LY294002 and wortmannin target the mTOR and PI3K/AKT pathways, respectively. These pathways are crucial for the regulation of protein synthesis, where FARSLA is involved in tRNA ligation. By inhibiting these pathways, these compounds reduce the protein synthesis rate, consequently decreasing the demand for FARSLA's enzymatic function.
Inhibitors like 5-Fluorouracil (5-FU) act through different mechanisms to affect FARSLA activity. 5-FU is an agent which is incorporated into RNA and disrupts RNA function and processing. Since FARSLA is involved in the ligation of tRNA, essential for protein synthesis, any disruption to RNA function can impact FARSLA activity indirectly. 5-FU can lead to a reduction in the availability of functional tRNA molecules for ligation, thus decreasing the enzymatic activity of FARSLA.